Behind the Price TagWho signed, what drugs are included, and why it matters
Not every drug—and not every manufacturer—will be affected the same way by the pricing agreements tied to the Trump administration. If your team supports patient affordability or plans revenue around drug access, you need clarity on which manufacturers and drugs are included and what that means operationally.
In our first episode, “Drug Pricing Agreements Under the Trump Administration,” you’ll get a focused breakdown of:
- Which manufacturers entered into pricing agreements, and which drugs are covered
- What the agreements were designed to achieve, and the pricing concessions involved
- How these decisions can affect patient access, affordability, and out-of-pocket costs
- Early ripple effects on provider reimbursement, financial counseling, and patient advocacy workflows
Watch the episode to understand what’s changing, who it affects, and how to prepare your organization.
Meet the Speaker
BreAnn Meadows
President, Revenue Integrity Services
Panacea Healthcare Solutions
Behind the Price Tag Podcast Series
Episode 2
Most Favored Nation (MFN) Pricing Explained
Coming Soon
Episode 3
CMS Policy Watch – GUARD (Part D) and GLOBE (Part B)
Coming Soon
